Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lifestyle

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,315 result(s) found for: Lifestyle. Displaying page 5 of 66.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-003347-28 Sponsor Protocol Number: MK-1654-005 Start Date*: 2019-10-03
    Sponsor Name:Merck Sharp & Dohme Corp
    Full Title: A Phase 2a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Participants Inoculated with Experimental Respiratory Syncytial Virus.
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2008-001583-36 Sponsor Protocol Number: AAG-G-H-0804 Start Date*: 2009-10-30
    Sponsor Name:Aesculap AG
    Full Title: Efficacy and Safety of Sangustop® as haemostatic agent versus a carrier-bound fibrin sealant during liver resection (ESSCALIVER)
    Medical condition: Male and female patients with indication for elective liver resection. The indication is to achieve haemostasis after liver resection.
    Disease: Version SOC Term Classification Code Term Level
    11.0 10062040 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000361-21 Sponsor Protocol Number: ARGX-113-1804 Start Date*: 2019-04-30
    Sponsor Name:Argenx BVBA
    Full Title: A Multicenter, Open-Label, Phase 2 Trial to Evaluate the Safety and Activity of Efgartigimod (ARGX-113) in Adult Patients with Primary Immune Thrombocytopenia
    Medical condition: Primary Immune Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004851 10074678 Primary immune thrombocytopenic purpura LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017874-20 Sponsor Protocol Number: MA-LA-IBS09-01 Start Date*: 2010-03-26
    Sponsor Name:AXCAN PHARMA SAS
    Full Title: Treatment of Diarrhea-predominant Irritable Bowel Syndrome with LACTEOL 340 mg : a pilot study evaluating safety and efficacy
    Medical condition: Diarrhea-predominant Irritable Bowel Syndrome
    Disease: Version SOC Term Classification Code Term Level
    12.1 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000818-29 Sponsor Protocol Number: MCP-103-403 Start Date*: 2016-08-08
    Sponsor Name:Ironwood Pharmaceuticals, Inc.
    Full Title: A Phase 4, Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study of the Effect of Linaclotide on Abdominal Girth in Participants with Irritable Bowel Syndrom...
    Medical condition: Irritable Bowel Syndrome with Constipation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10066868 Constipation predominant irritable bowel syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003834-34 Sponsor Protocol Number: ZP4207-17084 Start Date*: 2019-02-08
    Sponsor Name:Zealand Pharma A/S
    Full Title: A phase 3b, randomized, double-blind, crossover trial to compare the efficacy and safety of 2 different batches of subcutaneous dasiglucagon in patients with type 1 diabetes mellitus
    Medical condition: Type 1 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000346-61 Sponsor Protocol Number: DTG-01-01 Start Date*: 2017-02-20
    Sponsor Name:Blueclinical, Ltd.
    Full Title: A Phase II, Multicenter, Single-Arm, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of Triple Therapy with Dolutegravir plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected Subjects
    Medical condition: Human immunodeficiency virus (HIV)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10020194 HIV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002114-50 Sponsor Protocol Number: PEMDAC Start Date*: 2018-01-15
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: A multicenter phase II open label study to evaluate efficacy of concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma
    Medical condition: Patients suffering from metastatic uveal melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005115-26 Sponsor Protocol Number: SKY0402-C-208 Start Date*: 2008-01-21
    Sponsor Name:Pacira Pharmaceuticals Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control, Dose-Ranging Study to Evaluate the Safety, Efficacy, and Comparative Systemic Bioavailability of a Single Administration of ...
    Medical condition: post-operative pain management
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Prematurely Ended) DE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004486-27 Sponsor Protocol Number: X31005 Start Date*: 2018-02-12
    Sponsor Name:Associació Per a la Recerca Oncològica(APRO)
    Full Title: Phase II Study of Paclitaxel and TAK-228 in metastatic urothelial carcinoma (UC) and the impact of PI3K-mTOR pathway genomic alterations
    Medical condition: Metastatic urothelial carcinoma (UC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-001760-10 Sponsor Protocol Number: AGMT_NHL-15B Start Date*: 2016-10-24
    Sponsor Name:AGMT gGmbH
    Full Title: Phase II single-arm “window-of-opportunity” study of a combination of obinutuzumab (GA-101) and venetoclax (ABT-199) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
    Medical condition: Early relapsed or refractory diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    21.1 100000004864 10012856 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000508-40 Sponsor Protocol Number: PAT17-LOADS Start Date*: 2018-06-11
    Sponsor Name:Pharma Patent Kft.
    Full Title: Controlled randomized open label clinical study to compare the efficacy and the safety of the loading dose schedules of Vitamin D3 (colecalciferol) 30,000 IU product in deficient patients
    Medical condition: Vitamin-D deficient patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10047626 Vitamin D deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000805-26 Sponsor Protocol Number: PSYKFORSK_MAT-MDD Start Date*: 2021-11-19
    Sponsor Name:Østfold Hospital Trust
    Full Title: An Open-Label, Phase 2, Feasibility Study of Manualized MDMA-Assisted Psychotherapy in Subjects with Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004364-21 Sponsor Protocol Number: FYB202-03-01 Start Date*: 2020-05-12
    Sponsor Name:bioeq GmbH
    Full Title: A Randomised, Double-blind, Parallel-group, Phase 3 Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara in Patients with Moderate-to-S...
    Medical condition: Moderate-to-Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000795-19 Sponsor Protocol Number: HIPRA-HH-10 Start Date*: 2022-03-10
    Sponsor Name:HIPRA SCIENTIFIC
    Full Title: A PHASE IIB, DOUBLE-BLIND, RANDOMIZED, ACTIVE CONTROLLED, MULTI-CENTER, NON-INFERIORITY TRIAL TO ASSESS IMMUNOGENICITY AND SAFETY OF A BOOSTER VACCINATION WITH A RECOMBINANT PROTEIN RBD FUSION DIME...
    Medical condition: SARS-COV-2
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000554-10 Sponsor Protocol Number: GEM2014MAIN Start Date*: 2014-07-07
    Sponsor Name:Fundación PETHEMA
    Full Title: A randomized, open-label, national multicenter, phase III trial studying maintenance treatment with lenalidomide and dexamethasone versus lenalidomide, dexamethasone and MLN9708 after autologous he...
    Medical condition: Multiple Myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003222-92 Sponsor Protocol Number: NL67169.000.18 Start Date*: 2018-11-06
    Sponsor Name:Erasmus MC
    Full Title: Dendritic cells loaded with allogeneic tumor cell lysate (PheraLys™) in surgically resected pancreatic cancer patients (REACtiVe Trial)
    Medical condition: (borderline) resectable pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033578 Pancreas carcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002010-12 Sponsor Protocol Number: FIRE-6 Start Date*: 2019-04-30
    Sponsor Name:Klinikum der Ludwig-Maximilians-Universität München - Klinikum Großhadern (vertreten durch den kaufmännischen Direktor)
    Full Title: Avelumab added to FOLFIRI plus Cetuximab followed by Avelumab maintenance in patients with previously untreated RAS/BRAF wild-type metastatic colorectal cancer - The phase II FIRE-6-Avelumab study
    Medical condition: Avelumab added to FOLFIRI plus cetuximab followed by avelumab maintenance in patients with previously untreated RAS/BRAF wild-type metastatic colorectal cancer - the phase II FIRE-6-avelumab study
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001263-37 Sponsor Protocol Number: AGO/2016/003 Start Date*: 2016-06-23
    Sponsor Name:UZ Gent
    Full Title: Phase I trial of stereotactic body radiotherapy with concurrent pembrolizumab in metastatic urothelial cancer.
    Medical condition: Metastatic urothelial cancer
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000689-30 Sponsor Protocol Number: Pem-NSCLC Start Date*: 2018-08-02
    Sponsor Name:Med. Univ. Wien, Klinik f. Innere Med. I, Onkologie
    Full Title: Expression/DNA methylation of cancer testis antigens may predict response to pembrolizumab in pretreated NSCLC patients
    Medical condition: untreated patients with adenocarcinoma of the lung of advanced stage
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 03:45:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA